Arrowhead grabs RNAi delivery assets in Roche deal

Arrowhead Research ($ARWR) has parachuted into the bombarded field of RNAi therapeutics armed with Swiss drug giant Roche's assets. As part of Pasadena, CA-based Arrowhead's acquisition of Roche's stake in the gene-silencing drugs, the firm picked up three drug-delivery technologies. The technologies include a delivery platform called "Dynamic PolyCunjugates" (DPCs), a license to "SNALP" delivery tech from Tekmira Pharamceuticals ($TKM), and Roche-developed liposomal nanoparticle RNAi carriers. Roche is among several Big Pharma groups that have made major cuts to internal research of RNAi drugs. Release